Drugs / nL-CHCHD-001
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07423494 | Mar 2026 → Mar 2027 expected | amyotrophic lateral sclerosis | n-Lorem Foundation | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07095686 | Oct 2024 → Apr 2027 expected | amyotrophic lateral sclerosis | n-Lorem Foundation | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT06977451 | Jun 2024 → Jun 2027 expected | amyotrophic lateral sclerosis | n-Lorem Foundation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06392126 | Apr 2024 → Apr 2027 expected | amyotrophic lateral sclerosis | n-Lorem Foundation | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nL-CHCHD-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06977451 ↗ |
| Modality | Antisense oligonucleotide | “personalized antisense oligonucleotide (ASO) drug” NCT06977451 ↗ |